Hemab Therapeutics (HEMA) IPO Priced at $18 per Share

AI Summary

Hemab Therapeutics (HEMA) has set the price for its initial public offering (IPO) at $18 per share. This pricing will enable the company to raise significant capital as it enters the public market. The IPO is a crucial event as it marks Hemab's transition into a publicly traded entity, which can provide greater access to investment and resources for future growth. This event may impact investor sentiment and market dynamics related to biotech stocks.